- In April 2025, Allergan Aesthetics, an AbbVie company, announced the establishment of its inaugural AMI Training Centers Faculty. This initiative is part of the expansion of the Allergan Medical Institute (AMI), aiming to enhance medical education in aesthetics. The new faculty members are set to lead advanced training programs designed to elevate clinical techniques, patient safety, and business acumen among aesthetic providers
- In March 2024, Allergan Aesthetics, an AbbVie company, announced that the U.S. Food and Drug Administration (FDA) approved JUVÉDERM VOLUMA XC for injection in the temple region to improve moderate to severe temple hollowing in adults aged 21 and older. This approval marks the first and only hyaluronic acid (HA) dermal filler authorized for this specific indication, offering patients a non-surgical option for facial volume restoration in the upper face.
- In September 2023, Allergan Aesthetics, an AbbVie company, announced positive topline results from its second Phase 3 clinical trial evaluating onabotulinumtoxinA (BOTOX Cosmetic) for the treatment of platysma prominence. The study demonstrated significant improvement in the appearance of neck muscle bands, supporting the potential for a new indication in aesthetic medicine and paving the way for regulatory submissions.
- In May 2022, Ipsen Pharma was named the overall Pharma Industry Company of the Year for 2021 at the Pharma Industry Awards held in May 2022 in Dublin. This prestigious recognition highlights Ipsen’s innovation and excellence in the pharmaceutical sector. Additionally, Ipsen won the Best SME Pharma Company of the Year award for the fourth consecutive year, underscoring its consistent leadership in the industry.
